Universal leukocyte reduction.

Area of Science:

• Transfusion Medicine
• Hematology
• Infectious Disease Epidemiology

Background:

• Leukocyte reduction filters are used to remove white blood cells from blood products.
• Current guidelines in the United States reserve leukocyte reduction for documented clinical indications.
• Concerns exist regarding potential adverse outcomes linked to white blood cells in transfused components.

Purpose of the Study:

• To evaluate the current evidence supporting universal leukocyte reduction of blood components.
• To assess the necessity of leukocyte reduction for preventing specific transfusion-related risks.
• To determine if leukocyte reduction is indicated for preventing Creutzfeldt-Jakob disease transmission.

Main Methods:

• Review of existing clinical data and scientific literature.
• Analysis of evidence regarding transfusion-transmitted diseases, including prion diseases.
• Assessment of reported adverse events associated with leukocyte-containing blood products.

Main Results:

• No evidence suggests Creutzfeldt-Jakob disease or variant Creutzfeldt-Jakob disease are transmitted via transfusion.
• Leukocyte reduction has not been proven to reduce the transmission risk of these prion diseases.
• Insufficient clinical data exist to universally justify leukocyte reduction for all blood components.

Conclusions:

• Universal leukocyte reduction of blood components is not currently supported by robust clinical evidence.
• Specific indications, rather than routine application, should guide the use of leukocyte reduction.
• Further research is needed to clarify the benefits and risks of widespread leukocyte reduction.